30 closest matches · ranked by relevance
Neurofibromatosis 1 · Cutaneous Neurofibroma
Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…
Cutaneous Neurofibroma
Primary: Short Term Safety Profile - Adverse Events — 0; 20 Participants
Cutaneous Neurofibroma · Neurofibromatosis 1
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 35; 36; 49 Participants
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Neurofibromatosis 1
Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3
Neurofibromatoses
Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001
Neurofibromatosis
Primary: Percent Change From Baseline in Tumor Volume at 6 Months — 17 percentage change of tumor volume
Plexiform Neurofibroma
Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants
Dermatofibroma of Skin
Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale
Neurofibroma, Plexiform · Neurofibromatosis Type I
Primary: Median Time to Progression — 10.6; 14.5; 19.2; 13.3 Months
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Neurofibromatosis 2 · Vestibular Schwannoma
Primary: Estimated Volumetric Progression Free Survival at 12 Months — 70.6 Liklihood of PFS at 12 months
Neurofibromatosis · NF1 · Neurofibromas
Primary: Disease Response — 0; 0; 2; 1 Participants
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Primary: Percent of Participants With a 20% or More Change in Target Tumor Volume — 0; 8; 11; 0 Participants
Neurofibromatosis Type 1
Primary: Time to Disease Progression Based on Volumetric MRI — 15.4 Months
Neurofibromatosis · Neurofibromas
Primary: Disease Response — 13; 0; 0; 0 Participants
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Neurofibromatosis Type 1 · Precancerous Condition
Primary: Time to Disease Progression — 25.8; 29.2; 25.8 Months
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
Small Fiber Neuropathy
Primary: AFI-intensity After Nociceptive Stimulation — 0.60; 0.25; 0.50 unitless
Neurofibromatosis Type 1 · Reading Disabilities
Primary: Change From Baseline in WJ-III Basic Reading Normative Update (Woodcock Johnson Psychoeducational Battery - 3rd Edition; WJ-III NU) Standard Score at 15 Hours — 13.50…
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
Neurofibromatosis Type 2 · Vestibular Schwannomas
Primary: Expression Levels of p-S6 Based Immunohistochemistry (Histoscore) — 90 score
Nevi
Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Proportion of Enrolled Participants for Which we Are Able to Collect Data From the Medication Event Monitoring Systems (MEMS^TM) System for Two or More Cycles of…